A value-based budget impact model for dronedarone compared with other rhythm control strategies.
J Comp Eff Res
; 12(4): e220196, 2023 04.
Article
en En
| MEDLINE
| ID: mdl-36916711
ABSTRACT
Aim:
The budgetary consequences of increasing dronedarone utilization for treatment of atrial fibrillation were evaluated from a US payer perspective. Materials &methods:
A budget impact model over a 5-year time horizon was developed, including drug-related costs and risks for long-term clinical outcomes (LTCOs). Treatments included antiarrhythmic drugs (AADs; dronedarone, amiodarone, sotalol, propafenone, dofetilide, flecainide), rate control medications, and ablation. Direct comparisons and temporal and non-temporal combination scenarios investigating treatment order were analyzed as costs per patient per month (PPPM).Results:
By projected year 5, costs PPPM for dronedarone versus other AADs decreased by $37.69 due to fewer LTCOs, treatment with dronedarone versus ablation or rate control medications + ablation resulted in cost savings ($359.94 and $370.54, respectively), and AADs placed before ablation decreased PPPM costs by $242 compared with ablation before AADs. Conclusion Increased dronedarone utilization demonstrated incremental cost reductions over time.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Fibrilación Atrial
/
Amiodarona
Tipo de estudio:
Health_economic_evaluation
Límite:
Humans
Idioma:
En
Revista:
J Comp Eff Res
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos